Laura Steenpass

Dr. Laura Steenpass

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2016 in Scientific Reports
Verified
Journal Article
Open access
JSJana Stanurova
Jana Stanurova
ANAnika Neureiter
Anika Neureiter
MHMichaela Hiber
Michaela Hiber
HKHannah de Oliveira Kessler
Hannah de Oliveira Kessler
KSKristin Stolp
Kristin Stolp
LSLaura Steenpass
Laura Steenpass
Genomic imprinting is an epigenetic phenomenon resulting in parent-of-origin-specific gene expression that is regulated by a differentially methylated region. Gene mutations or failures in the imprinting process lead to the development of imprinting disorders, such as Angelman syndrome. The symptoms of Angelman syndrome are caused by the absence of functional UBE3A protein in neurons of the brain. To create a human neuronal model for Angelman syndrome, we reprogrammed dermal fibroblasts of a patient carrying a defined three-base pair deletion in UBE3A into induced pluripotent stem cells (iPSCs). In these iPSCs, both parental alleles are present, distinguishable by the mutation and express UBE3A. Detailed characterization of these iPSCs demonstrated their pluripotency and exceptional stability of the differentially methylated region regulating imprinted UBE3A expression. We observed strong induction of SNHG14 and silencing of paternal UBE3A expression only late during neuronal differentiation, in vitro. This new Angelman syndrome iPSC line allows to study imprinted gene regulation on both parental alleles and to dissect molecular pathways affected by the absence of UBE3A protein.

1 February 2019 in Experimental Cell Research
Verified
Journal Article
Open access
MSM. Schwermer
M. Schwermer
MHM. Hiber
M. Hiber
SDS. Dreesmann
S. Dreesmann
ARA. Rieb
A. Rieb
JTJ. Theißen
J. Theißen
LSLaura Steenpass
Laura Steenpass
In retinoblastoma research tumor-derived cell lines remain an important model to investigate tumorigenesis and new therapy options, due to limited tumor material and lack of adequate animal models. A panel of 10 retinoblastoma cell lines was characterized with respect to mutation, methylation and expression of RB1 and MYCN. These established retinoblastoma cell lines represent the most frequent types of RB1 inactivation and together with the MYCN amplification status, three classes can be distinguished: RB1mut/MYCNnonA, RB1mut/MYCNA and RB1wt/MYCNA. MYCN amplification was identified in five cell lines, whereby two of them, RB522 and RB3823, harbor no aberration in RB1. Targeted sequencing of 160 genes often mutated in cancer identified only few variants in tumor-associated genes other than in RB1. None of these variants was recurrent. mRNA expression analyses of retinal markers, cell cycle regulators and members of the TP53 signaling pathway revealed a high variability between cell lines but no class-specific differences. The here presented thorough validation of retinoblastoma cell lines, including microsatellite analysis for cell line authentication, provides the basis for further in vitro studies on retinoblastoma.

20 July 2022 in F1000Research
Verified
Journal Article
Open access
PDF file
JKJulia Koblitz
Julia Koblitz
WDWilhelm G. Dirks
Wilhelm G. Dirks
SESonja Eberth
Sonja Eberth
SNStefan Nagel
Stefan Nagel
LSLaura Steenpass
Laura Steenpass
CPClaudia Pommerenke
Claudia Pommerenke
Human and animal cell lines serve as model systems in a wide range of life sciences such as cancer and infection research or drug screening. Reproducible data are highly dependent on authenticated, contaminant-free cell lines, no better delivered than by the official and certified biorepositories. Offering a web portal to high-throughput information on these model systems will facilitate working with and comparing to these references by data otherwise dispersed at different sources. We here provide DSMZCellDive to access a comprehensive data source on human and animal cell lines, freely available at celldive.dsmz.de. A wide variety of data sources are generated such as RNA-seq transcriptome data and STR (short tandem repeats) profiles. Several starting points ease entering the database via browsing, searching or visualising. This web tool is designed for further expansion on meta and high-throughput data to be generated in future. Explicated examples for the power of this novel tool include analysis of B-cell differentiation markers, homeo-oncogene expression, and measurement of genomic loss of heterozygosities by an enlarged STR panel of 17 loci. Sharing the data on cell lines by the biorepository itself will be of benefit to the scientific community since it (1) supports the selection of appropriate model cell lines, (2) ensures reliability, (3) avoids misleading data, (4) saves on additional experimentals, and (5) serves as reference for genomic and gene expression data.

6 February 2024 in Cells
Verified
Journal Article
Open access
PDF file
CPClaudia Pommerenke
Claudia Pommerenke
SNStefan Nagel
Stefan Nagel
JHJosephine Haake
Josephine Haake
AKAnne Leena Koelz
Anne Leena Koelz
MCMatthias Christgen
Matthias Christgen
SESonja Eberth
Sonja Eberth
Continuous cell lines are important and commonly used in vitro models in breast cancer (BC) research. Selection of the appropriate model cell line is crucial and requires consideration of their molecular characteristics. To characterize BC cell line models in depth, we profiled a panel of 29 authenticated and publicly available BC cell lines by mRNA-sequencing, mutation analysis, and immunoblotting. Gene expression profiles separated BC cell lines in two major clusters that represent basal-like (mainly triple-negative BC) and luminal BC subtypes, respectively. HER2-positive cell lines were located within the luminal cluster. Mutation calling highlighted the frequent aberration of TP53 and BRCA2 in BC cell lines, which, therefore, share relevant characteristics with primary BC. Furthermore, we showed that the data can be used to find novel, potential oncogenic fusion transcripts, e.g., FGFR2::CRYBG1 and RTN4IP1::CRYBG1 in cell line MFM-223, and to elucidate the regulatory circuit of IRX genes and KLF15 as novel candidate tumor suppressor genes in BC. Our data indicated that KLF15 was activated by IRX1 and inhibited by IRX3. Moreover, KLF15 inhibited IRX1 in cell line HCC-1599. Each BC cell line carries unique molecular features. Therefore, the molecular characteristics of BC cell lines described here might serve as a valuable resource to improve the selection of appropriate models for BC research.

26 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
DKDeniz Kanber
Deniz Kanber
JWJulia Woestefeld
Julia Woestefeld
HDHannah Döpper
Hannah Döpper
MBMorgane Bozet
Morgane Bozet
ABAlexandra Brenzel
Alexandra Brenzel
LSLaura Steenpass
Laura Steenpass
Retinoblastoma is a tumor of the eye in children under the age of five caused by biallelic inactivation of the RB1 tumor suppressor gene in maturing retinal cells. Cancer models are essential for understanding tumor development and in preclinical research. Because of the complex organization of the human retina, such models were challenging to develop for retinoblastoma. Here, we present an organoid model based on differentiation of human embryonic stem cells into neural retina after inactivation of RB1 by CRISPR/Cas9 mutagenesis. Wildtype and RB1 heterozygous mutant retinal organoids were indistinguishable with respect to morphology, temporal development of retinal cell types and global mRNA expression. However, loss of pRB resulted in spatially disorganized organoids and aberrant differentiation, indicated by disintegration of organoids beyond day 130 of differentiation and depletion of most retinal cell types. Only cone photoreceptors were abundant and continued to proliferate, supporting these as candidate cells-of-origin for retinoblastoma. Transcriptome analysis of RB1 knockout organoids and primary retinoblastoma revealed gain of a retinoblastoma expression signature in the organoids, characterized by upregulation of RBL1 (p107), MDM2, DEK, SYK and HELLS. In addition, genes related to immune response and extracellular matrix were specifically upregulated in RB1-negative organoids. In vitro retinal organoids therefore display some features associated with retinoblastoma and, so far, represent the only valid human cancer model for the development of this disease.

1 July 2025 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
JHJosephine Haake
Josephine Haake
LSLaura Steenpass
Laura Steenpass
Human pluripotent stem cells (hPSCs) are important tools in preclinical research and disease modeling. Valid results can only be obtained using thoroughly quality-controlled hPSCs, which includes ensuring chromosomal stability. Chromosomal aberrations, which frequently arise during reprogramming, gene editing, or maintenance cultivation, can compromise the utility of these cells in research and therapeutic applications. Although traditional G-banding remains a valuable genome-wide analysis method, its limited resolution necessitates complementary approaches. SNP array analysis offers a high-resolution alternative, providing a more detailed genomic overview. We present a practical and user-friendly guide for detecting chromosomal aberrations using Illumina’s GenomeStudio, offering an easy-to-follow protocol to simplify quality control workflows for researchers with minimal bioinformatics expertise. Although SNP array analysis for hPSC quality control is not novel, this step-by-step guide highlights critical quality control metrics, thresholds, and values, streamlining the process to make it more accessible and efficient for broader adoption. In 32 hPSCs, we identified chromosomal aberrations in nine, including the frequently reported gain of 20q11.21—a common anomaly in hPSC cultures. Examples from our routine practices underscore the importance of monitoring chromosomal integrity. This guide serves as a practical resource for standardizing and enhancing quality control processes, ensuring the genomic stability of hPSCs for research and clinical applications.